.jpg)
Perzea Launch Strengthens Hetero Healthcare’s Oncology Leadership Through Partnership with Enzene Biosciences
Hetero Healthcare and Enzene Biosciences have introduced Perzea to expand affordable access to pertuzumab therapy for HER2+ breast cancer, leveraging EnzeneX™ technology.
Hetero Healthcare and Enzene launched Perzea, India’s most affordable Pertuzumab biosimilar
Hyderabad (Telangana) [India], September 25: Hetero Healthcare Limited, in strategic collaboration with Enzene Biosciences, has launched Perzea, India’s most affordable Pertuzumab biosimilar. The introduction of this targeted therapy for HER2-positive breast cancer demonstrates the synergy between two healthcare leaders committed to advanced cancer treatment accessibility.
Innovation Meets Affordability
Pertuzumab plays a vital role in the standard of care for HER2-positive breast cancer worldwide. By leveraging Enzene’s patented EnzeneX technology, Perzea becomes not only affordable but also reliable in terms of quality and production efficiency. This innovation-driven partnership sets new standards for biologics in India.
) platform for commercial biologics supply. Its operations in Pune (India) and New Jersey (USA) focus on biologics innovation and affordability. Visit:
